Stay updated with breaking news from Masamitsu Kitase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of...
Transgene and NEC are planning to extend their randomized phase 1 trial into a phase 2 study in 2024 to further demonstrate the potential of TG4050, a neoantigen vaccine for head and neck cancers.
Nagasaki University and NEC OncoImmunity (NOI), a leading artificial intelligence (AI) company, have announced that they will collaborate to use NOI’s AI platform to design universal vaccines against highly pathogenic and tropical infectious diseases. The collaboration between NOI and Nagasaki University aims to harness the power of adv...
Nagasaki University and NEC OncoImmunity (NOI), a leading artificial intelligence (AI) company, have announced their collaboration to utilise NOI's AI platform in the creation of universal vaccines against highly pathogenic and tropical infectious diseases. Click to read more...
TOKYO, Aug 21, 2023 - (JCN Newswire) - Nagasaki University and NEC OncoImmunity (NOI), a leading artificial intelligence (AI) company, have announced that they will collaborate to use NOI's AI platform to design universal vaccines against highly pathogenic and tropical infectious diseases.The collaboration between NOI and Nagasaki University aims to harness the power of advanced AI to optimize vaccine designs...